EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension
NCT ID: NCT02092818
Last Updated: 2019-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1316 participants
OBSERVATIONAL
2014-05-31
2018-06-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
NCT02759419
A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
NCT04813926
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
NCT02891850
Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)
NCT02428985
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
NCT01784562
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Patients who have been prescribed Adempas for a medically appropriate use
Riociguat (Adempas, BAY63-2521)
The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Riociguat (Adempas, BAY63-2521)
The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Multiple Locations, , Argentina
Multiple Locations, , Australia
Multiple Locations, , Austria
Multiple Locations, , Belgium
Multiple Locations, , Canada
Multiple Locations, , Colombia
Multiple Locations, , Czechia
Multiple Locations, , Denmark
Multiple Locations, , Estonia
Multiple Locations, , Finland
Multiple Locations, , France
Multiple Locations, , Germany
Multiple Locations, , Greece
Multiple Locations, , Ireland
Multiple Locations, , Italy
Multiple Locations, , Luxembourg
Multiple Locations, , Netherlands
Multiple Locations, , Norway
Multiple Locations, , Portugal
Multiple Locations, , Russia
Multiple Locations, , Saudi Arabia
Multiple Locations, , Slovakia
Multiple Locations, , Spain
Multiple Locations, , Sweden
Multiple Locations, , Switzerland
Multiple Locations, , Taiwan
Multiple Locations, , Turkey (Türkiye)
Multiple Locations, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find results for studies related to Bayer products.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD1301
Identifier Type: OTHER
Identifier Source: secondary_id
16657
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.